-
News | 2022.05.12
SAVE THE DATE : Pasteur Innov’day - First edition July 7th, 2022!
Fundamentally applied!From basic research to product: the innovation potential of the Institut Pasteur’s continuum Come and meet our researchers to discover some of our emblematic innovations. Integrating complementary expertise from technology platforms and research laboratories, these successes are the result of collaborations involving different teams.Are you a small or medium-sized...
-
News | 2022.05.12
SARS-CoV 2: A booster with a "Lenti-COVID" vaccine candidate induces protective immunity in the respiratory mucosa in a preclinical model
Scientist at the Institut Pasteur- TheraVectys Joint Laboratory have demonstrated the efficacy of their lentiviral candidate vaccine “Lenti-COVID”, administered as an intranasal booster dose six months after primary vaccination with a messenger RNA vaccine, in a pre-clinical model. This intranasal booster induces protective immunity in the respiratory mucosa. These results pave the way for...
-
News | 2022.05.16
mRNA Access: researchers of the Institut Pasteur can benefit from Moderna's mRNA platform for global health
The Institut Pasteur and Moderna have signed a Master Material Transfer Agreement (MMTA) to enable researchers of the Institut Pasteur to have access to Moderna's preclinical manufacturing capabilities and its research and development expertise. The objective is to jointly explore the possibility of mRNA to tackle the world's greatest global public health threats. Institut Pasteur...
-
Document de presse | 2022.05.18
Phage Therapy: A Model to Predict Its Efficacy against Pathogenic Bacteria
Antibiotic resistance represents a major public health challenge, associated with a high mortality rate. While bacteriophages – viruses that kill bacteria – could be a solution for fighting antibiotic-resistant pathogens, various obstacles stand in the way of their clinical development. To overcome them, researchers from Inserm, Université Sorbonne Paris Nord and Université Paris-Cité at the IAME...
-
Article | 2022.05.30
Afroscreen Project : boosting variant surveillance in 13 african countries
The Agence française de développement (AFD) and ANRS | Maladies infectieuses émergentes, in partnership with the Institut Pasteur, IRD, and laboratories across 13 African countries, are launching the joint AFROSCREEN project. This project meets an urgent need for surveillance of the development of SARS-CoV-2 variants and other emerging pathogens by bolstering laboratory genomic sequencing...
-
Article | 2022.05.31
Ethics and Compliance Committee
At its meeting on March 5, 2018, the Board of Governors adopted a revised Charter for the Prevention and Management of Conflicts of Interest. At the same time, the Board decided to set up an Ethics and Compliance Committee tasked with issuing opinions and recommendations to guide the Board of Governors and the President and ensuring that the principles in the Charter are applied.
-
Document de presse | 2022.05.23
Stromal cells, maestros of the intestine
The intestine is responsible for absorbing nutrients while protecting the body from external aggression, a task performed by a complex intestinal barrier. Scientists from the Institut Pasteur demonstrated in a mouse model that a population of tissue-resident cells known as stromal cells is crucial for the development of a functional intestinal barrier in the first few weeks after birth. Absence...
-
News | 2022.06.07
Small/medium-sized companies in the healthcare sector: see you at Pasteur Innov’ Day!
Are you a small or medium-sized company in the healthcare sector and are you looking for a collaborator of choice to overcome a scientific or technological barrier? Register for Pasteur Innov' Day on July 7, 2022, and come and discover some of our iconic innovations. The Pasteur Innov’ day is an opportunity to meet our scientific experts and business managers to discuss your innovation projects...
-
Document de presse | 2022.06.07
Institut Pasteur and MSDAVENIR sign a partnership to improve strategies for controlling the spread of vector-borne viral diseases like Zika
The Institut Pasteur and MSDAVENIR, a health research endowment fund by MSD, signed an important partnership to anticipate responses to future vector-borne viral epidemics today. The partnership, worth more than €1.7 million, will support the INTRANZIGEANT project led by Dr. Louis Lambrechts, head of the Virus-Insect Interactions Unit, and Xavier Montagutelli, head of the Mouse Genetics...
-
News | 2022.06.08
The role of social sciences in the response to an epidemic: the example of the COVID-19 pandemic
A lesser known but equally crucial dimension in managing and responding to an epidemic is social sciences in health, which can shed light on populations' understanding, perception and acceptance of the risks associated with diseases. The COVID-19 pandemic is no exception. As the disease spread across the planet, clear differences in perception by populations were observed in different countries,...
